INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.07
-1.07 (-3.67%)
At close: 4:00PM EDT

27.30 -0.77 (-2.74%)
After hours: 6:15PM EDT

Stock chart is not supported by your current browser
Previous Close29.14
Open28.80
Bid26.02 x 1000
Ask27.38 x 800
Day's Range28.07 - 28.95
52 Week Range11.31 - 33.13
Volume389,726
Avg. Volume772,579
Market Cap2.18B
Beta (3Y Monthly)3.95
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Insmed Announces Proposed Public Offering of Common Stock
    PR Newswire8 hours ago

    Insmed Announces Proposed Public Offering of Common Stock

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $25.5 million of its common stock at the public offering price, less the underwriting discounts and commissions. William H. Lewis, the Company's Chairman and Chief Executive Officer, intends to grant the underwriters a 30-day option to purchase up to $12 million of Insmed common stock held by Mr. Lewis also at the public offering price.

  • New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    PR Newswire8 hours ago

    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

    BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease, demonstrating that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.

  • Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
    PR Newswire14 days ago

    Insmed Reports First Quarter 2019 Financial Results and Provides Business Update

    -- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 -- -- Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $90 Million ...

  • Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019
    PR Newswire21 days ago

    Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

    BRIDGEWATER, N.J., April 30, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results on Tuesday, May 7, 2019. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2019 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 6243203.

  • Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    PR Newswirelast month

    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio

    BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension). The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by the USPTO for ARIKAYCE in MAC lung disease and the second with an expiry date of May 15, 2035.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    PR Newswirelast month

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch

    BRIDGEWATER, N.J., April 8, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary net product sales for the first quarter of 2019.  ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. "We continue to be very pleased with the U.S. launch progress of ARIKAYCE and the positive feedback received from the refractory MAC lung disease community," said Will Lewis, Chairman and Chief Executive Officer of Insmed.

  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire2 months ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., April 2, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on April 1, 2019 to purchase an aggregate 26,260 shares of Insmed common stock at an exercise price of $29.09 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
    PR Newswire2 months ago

    Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.

  • Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire2 months ago

    Insmed to Present at the H.C. Wainwright Global Life Sciences Conference

    BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 10:50 a.m. BST. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed Announces Management Changes
    PR Newswire2 months ago

    Insmed Announces Management Changes

    BRIDGEWATER, N.J. , March 27, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

  • Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
    PR Newswire3 months ago

    Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales of $9.2 Million for the Fourth Quarter and Full Year 2018-- --Company Provides Full-Year 2019 ARIKAYCE Revenue Guidance of $80 ...

  • Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference
    PR Newswire3 months ago

    Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

    BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Leerink Partners 8th Annual Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 3:30 p.m. ET. Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

  • Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019
    PR Newswire3 months ago

    Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

    BRIDGEWATER, N.J. , Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that ...

  • GlobeNewswire3 months ago

    Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
    PR Newswire4 months ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

  • ACCESSWIRE6 months ago

    Healthcare Stocks with Turnaround Potential

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...

  • GlobeNewswire6 months ago

    Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    Insmed Announces Changes to its Board of Directors

    Elizabeth McKee Anderson has been appointed to Insmed’s board of directors, succeeding Myrtle Potter, who has retired as a member of the board following four years of service to Insmed due to the demands of her current role as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. “I am excited to join Insmed’s board and bring my extensive strategic marketing and market access experience to the Company as it executes the launch of ARIKAYCE® (amikacin liposome inhalation suspension) and pursues potential regulatory submissions in Europe and Japan,” said Anderson. Donald Hayden, Jr. has stepped down as chairman of the board after 13 years of distinguished service and will continue to serve as a director.

  • GlobeNewswire6 months ago

    Insmed to Present at Three November Conferences

    BRIDGEWATER, N.J., Nov. 06, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare.

  • GlobeNewswire7 months ago

    Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

    —Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch— BRIDGEWATER, N.J., Oct. 30, 2018 -- Insmed.